Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?
SummaryProstate cancer is the most common non-cutaneous cancer in the United States. Although most are diagnosed at earlier stages of disease, a significant number of patients will eventually progress to metastatic androgen-independent prostate cancer (AIPC) and will receive chemotherapy. The benefit of chemotherapy in overall survival has been demonstrated in studies utilizing docetaxel. However, duration of response is short and therapeutic options are limited after taxane failure. There is a need for effective chemotherapeutic agents in the second-line setting, either alone or in combination. Some of these regimens may also ultimately translate to the front-line chemotherapeutic setting as an alternative or perhaps in combination with a taxane.
Aragon-Ching
Jeanny B
JB
Medical Oncology Branch, National Cancer Institute, National Institutes of Health.
Dahut
William L
WL
Cancer. 2006 Mar 1;106(5):1041-6
16456811
BJU Int. 2005 Aug;96(3):296-302
16042717
Expert Opin Investig Drugs. 2000 Jun;9(6):1373-82
11060749
J Clin Oncol. 2005 Nov 10;23(32):8247-52
16278480
J Clin Oncol. 2001 Jan 1;19(1):44-53
11134194
Eur J Cancer. 1993;29A(15):2094-6
7507687
Cancer. 2003 Feb 1;97(3):561-7
12548597
Am J Ther. 2004 Jul-Aug;11(4):288-94
15266221
Cancer Pract. 1997 Jul-Aug;5(4):258-63
9250085
Jpn J Clin Oncol. 2000 Sep;30(9):377-84
11095134
Semin Oncol. 1999 Apr;26(2):162-73
10597727
Cancer Chemother Pharmacol. 1998;42(2):142-8
9654114
Ann Oncol. 2003 Oct;14(10):1518-24
14504052
Oncology. 2005;68(1):2-9
15741753
Cancer. 2006 Aug 15;107(4):738-45
16826591
Cancer. 2000 Jun 15;88(12 Suppl):3009-14
10898345
J Clin Oncol. 2007 Feb 20;25(6):669-74
17308271
Am J Clin Oncol. 1983 Apr;6(2):203-5
6681933
J Clin Oncol. 1997 Jul;15(7):2691-700
9215842
Cancer. 2003 Nov 1;98(9):1842-8
14584065
J Clin Oncol. 2005 Mar 1;23(7):1439-46
15735119
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552-6
8105478
Cancer Chemother Pharmacol. 1995;36(6):451-8
7554035
J Clin Oncol. 2005 Dec 1;23(34):8724-9
16314632
CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
4625049
Cancer. 2006 Jan 1;106(1):58-62
16329138
N Engl J Med. 2006 Sep 7;355(10):983-91
16957145
Biochemistry. 2002 Mar 26;41(12):3870-4
11900528
N Engl J Med. 2004 Oct 7;351(15):1513-20
15470214
Cancer Res. 1994 Aug 1;54(15):4118-22
8033145
Br J Cancer. 2004 Apr 5;90(7):1312-7
15054447
Cancer Treat Rep. 1986 Apr;70(4):541-2
3698053
JAMA. 2005 Jul 13;294(2):238-44
16014598
Cancer. 1993 Feb 1;71(3 Suppl):1098-109
7679039
J Clin Oncol. 2004 May 15;22(10):2015-25
15143095
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
BJU Int. 2005 Nov;96(7):990-4
16225514
Urology. 2006 Jun;67(6):1235-40
16765185
Ann Oncol. 1998 Dec;9(12):1315-22
9932162
Urology. 1980 Feb;15(2):123-6
7188818
J Clin Oncol. 2001 May 1;19(9):2509-16
11331330
J Clin Oncol. 1996 Jun;14(6):1756-64
8656243
Trends Pharmacol Sci. 1992 Apr;13(4):134-6
1350385
Exp Mol Med. 2006 Jun 30;38(3):320-4
16819291
Ann Oncol. 1999 Nov;10(11):1307-10
10631457
Invest New Drugs. 2005 Jan;23(1):79-84
15528984
BJU Int. 2005 Nov;96(7):985-9
16225513
J Clin Oncol. 2004 Jul 1;22(13):2532-9
15226321
Eur J Cancer. 2002 Aug;38(12):1626-32
12142053
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
17237035
Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1557-64
498155
Urology. 1997 Jul;50(1):93-9
9218025
Ann Oncol. 2004 Nov;15(11):1613-21
15520061